advertisement
87
Showing records 1 to 25 | Display all abstracts from91196 Relationship between Intraocular Pressure and Coffee Consumption in a Japanese Population without Glaucoma: The Nagahama Study
Nakano E
Ophthalmology. Glaucoma 2021; 4: 268-276
91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Stalmans I
Clinical Ophthalmology 2020; 14: 3675-3680
91433 Intraocular Pressure, Glaucoma, and Dietary Caffeine Consumption: A Gene-Diet Interaction Study from the UK Biobank
Kim J
Ophthalmology 2021; 128: 866-876
90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Medeiros FA
Ophthalmology 2020; 127: 1627-1641
91853 OCT Signal Enhancement with Deep Learning
Lazaridis G
Ophthalmology. Glaucoma 2021; 4: 295-304
90869 Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
The Lancet. Global health 2021; 9: e144-e160
91853 OCT Signal Enhancement with Deep Learning
Lazaridis G
Ophthalmology. Glaucoma 2021; 4: 295-304
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Inatani M
Advances in Therapy 2021; 38: 1116-1129
91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Ahmed IIK
Ophthalmology 2021; 128: 857-865
90888 Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study
The Lancet. Global health 2021; 9: e130-e143
91168 Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study
Founti P
Ophthalmology 2020; 127: 1642-1651
91264 Glaucoma-Related Adverse Events at 10 Years in the Infant Aphakia Treatment Study: A Secondary Analysis of a Randomized Clinical Trial
Freedman SF
JAMA ophthalmology 2021; 139: 165-173
91853 OCT Signal Enhancement with Deep Learning
Lorenzi M
Ophthalmology. Glaucoma 2021; 4: 295-304
91196 Relationship between Intraocular Pressure and Coffee Consumption in a Japanese Population without Glaucoma: The Nagahama Study
Miyake M
Ophthalmology. Glaucoma 2021; 4: 268-276
91433 Intraocular Pressure, Glaucoma, and Dietary Caffeine Consumption: A Gene-Diet Interaction Study from the UK Biobank
Aschard H
Ophthalmology 2021; 128: 866-876
91624 Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
Lemij H
Clinical Ophthalmology 2020; 14: 3675-3680
90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Walters TR
Ophthalmology 2020; 127: 1627-1641
91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Rhee DJ
Ophthalmology 2021; 128: 857-865
91168 Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study
Bunce C
Ophthalmology 2020; 127: 1642-1651
91264 Glaucoma-Related Adverse Events at 10 Years in the Infant Aphakia Treatment Study: A Secondary Analysis of a Randomized Clinical Trial
Beck AD
JAMA ophthalmology 2021; 139: 165-173
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Higashide T
Advances in Therapy 2021; 38: 1116-1129
91853 OCT Signal Enhancement with Deep Learning
Lorenzi M
Ophthalmology. Glaucoma 2021; 4: 295-304
91469 Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract
Jones J
Ophthalmology 2021; 128: 857-865
91853 OCT Signal Enhancement with Deep Learning
Mohamed-Noriega J
Ophthalmology. Glaucoma 2021; 4: 295-304
91168 Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study
Khawaja AP
Ophthalmology 2020; 127: 1642-1651
